TY - T1的中风的患病率在社区个人在美国:1999 - 2018 (S19.009) JF -首页神经学乔-神经学做- 10.1212 / WNL。0000000000202626六世- 100 - 17补充2 SP - 2533 AU -威尔斯Andres AU -亚伦Rothstein盟冬青Elser AU -凯利斯隆AU -斯科特Kasner AU -丽贝卡·戈特斯曼AU -安德里亚·施耐德Y1 - 2023/04/25 UR - //www.ez-admanager.com/content/100/17_Supplement_2/2533.abstract N2 -目的:评估中风的首页患病率在社区个人在美国1999年和2018年之间使用具有全国代表性的样本。背景:缺乏近期数据趋势中风患病率在社区住宅个人之前在美国流行病学报告显示降低中风发病率和减少中风死亡率。准确和最新的代表估计中风的患病率需要通知的公共卫生干预措施。设计/方法:我们进行了一系列的横断面分析数据从2197名参与者年龄在20 + 1999 - 2018年全国健康和营养调查(NHANES)自我报告中风的历史。我们计算的年龄标准化中风患病率超过四年时代总的来说,和年龄分层,性别,种族/民族。使用美国社区调查公共使用微数据样本从2017年到2018年,我们估计的人数影响中风。结果:中风的整体年龄标准化患病率为3.1% (95% ci: 2.9% - -3.3%)从1999 - 2002到2015 - 2018,相当于740万(7.0 -790万)影响个人。中风的年龄标准化发病率稳定在1999 - 2002 - 2015 - 2018 (p-value-for-linear-trend-across-four-year-epochs = 0.332)。中风的年龄标准化患病率从1999 - 2002 - 2015 - 2018是高于老年人(≥60岁:7.7%,7.2% -8.2%)相比,年轻人(热带病岁:0.4%,0.3%,-0.5%;40岁至59岁的岁:2.0%,1.8% - -2.3%),在非西班牙裔黑人个体(4.7%,4.3%,-5.1%)比其他种族/民族(非西班牙裔白人:2.9%,2.7%,-3.2%; Mexican American: 2.6%, 2.3%–3.0%; Other: 3.5%, 2.8%–4.2%; Asian American: 1.7%, 1.3%–2.3%), and was similar by sex (men: 2.9%, 2.7%–3.2%; women: 3.2%, 3.0%–3.5%). The prevalence of stroke in each age, sex, and race/ethnicity group was stable from 1999–2002 to 2015–2018Conclusions: The age-standardized prevalence of stroke in the non-institutionalized civilian adult population of the U.S. has not significantly changed between 1999 and 2018. In the context of other reports this likely reflects a combination of decreasing stroke incidence and improved stroke outcomes.Disclosure: Dr. Andres has nothing to disclose. Dr. Rothstein has nothing to disclose. Dr. Elser has nothing to disclose. The institution of Dr. Sloane has received research support from National Center for Advancing Translational Sciences of the National Institutes of Health: KL2TR001879. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol-Myers Squibb. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Diamedica. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Javelin. Dr. Kasner has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for UpToDate. The institution of Dr. Kasner has received research support from Bristol-Myers Squibb. The institution of Dr. Kasner has received research support from Medtronic. The institution of Dr. Kasner has received research support from WL Gore. Dr. Gottesman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology. The institution of Dr. Gottesman has received research support from NIH. Dr. Schneider has nothing to disclose. ER -